ZA882717B - 17beta-(cyclopropylamino)-androst-5-eb-3beta-ol and related compounds useful as c17-20 lyase inhibitors - Google Patents

17beta-(cyclopropylamino)-androst-5-eb-3beta-ol and related compounds useful as c17-20 lyase inhibitors

Info

Publication number
ZA882717B
ZA882717B ZA882717A ZA882717A ZA882717B ZA 882717 B ZA882717 B ZA 882717B ZA 882717 A ZA882717 A ZA 882717A ZA 882717 A ZA882717 A ZA 882717A ZA 882717 B ZA882717 B ZA 882717B
Authority
ZA
South Africa
Prior art keywords
androst
cyclopropylamino
17beta
3beta
related compounds
Prior art date
Application number
ZA882717A
Other languages
English (en)
Inventor
R. Angelastro Michael
R. Blohm Thomas
Original Assignee
Merrell Dow Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc. filed Critical Merrell Dow Pharmaceuticals Inc.
Publication of ZA882717B publication Critical patent/ZA882717B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Detergent Compositions (AREA)
ZA882717A 1987-04-22 1988-04-18 17beta-(cyclopropylamino)-androst-5-eb-3beta-ol and related compounds useful as c17-20 lyase inhibitors ZA882717B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4117287A 1987-04-22 1987-04-22

Publications (1)

Publication Number Publication Date
ZA882717B true ZA882717B (en) 1988-10-17

Family

ID=21915133

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA882717A ZA882717B (en) 1987-04-22 1988-04-18 17beta-(cyclopropylamino)-androst-5-eb-3beta-ol and related compounds useful as c17-20 lyase inhibitors

Country Status (19)

Country Link
EP (1) EP0288053B1 (fr)
JP (1) JP2711672B2 (fr)
KR (1) KR960015037B1 (fr)
CN (1) CN88102176A (fr)
AT (1) ATE67211T1 (fr)
AU (1) AU606677B2 (fr)
CA (1) CA1326234C (fr)
DE (1) DE3864725D1 (fr)
DK (1) DK217588A (fr)
ES (1) ES2038712T3 (fr)
FI (1) FI88397C (fr)
GR (1) GR3002713T3 (fr)
HU (1) HU198511B (fr)
IL (1) IL86139A (fr)
NO (1) NO169346C (fr)
NZ (1) NZ224288A (fr)
PH (1) PH24090A (fr)
PT (1) PT87294B (fr)
ZA (1) ZA882717B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891367A (en) * 1987-04-22 1990-01-02 Merrell Dow Pharmaceuticals Inc. 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US4954488A (en) * 1989-06-14 1990-09-04 Merrell Dow Pharmaceuticals Inc. Method of treating hyperaldosteronism using 17β-cyclopropylaminoandrostene derivatives
US4966898A (en) * 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US5252319A (en) * 1990-06-12 1993-10-12 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5256408A (en) * 1990-06-12 1993-10-26 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5209926A (en) * 1990-06-12 1993-05-11 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
JP2742331B2 (ja) * 1992-03-31 1998-04-22 ブリテイツシユ・テクノロジー・グループ・リミテツド 癌治療に有用な１７位置換ステロイド
US5486511A (en) * 1993-05-25 1996-01-23 Merrell Dow Pharmaceuticals Inc. 4-amino-17β-(cyclopropyloxy)androst-4-en-3-one, 4-amino-17β-(cyclopropylamino)androst-4-en-3-one and related compounds as C17-20 lyase and 5α-reductase
ATE327237T1 (de) 2000-11-17 2006-06-15 Takeda Pharmaceutical Imidazol derivate, ihre herstellung und ihre verwendung
EP1344777B1 (fr) 2000-11-20 2011-03-16 Takeda Pharmaceutical Company Limited Derives de l'imidazole, leur procede de preparation et leur application
CA2431171A1 (fr) 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Derives thiazole substitues porteurs de groupes 3-pyridyl, procede d'elaboration et leur utilisation
CA2765983C (fr) 2009-06-26 2017-11-14 Novartis Ag Derives d'imidazolidin-2-one 1,3-disubstitues en tant qu'inhibiteurs de cyp 17
AU2011285724B2 (en) 2010-08-04 2015-01-22 Pellficure Pharmaceuticals, Inc. Combination therapy for the treatment of prostate carcinoma
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
CN103649073B (zh) 2011-04-28 2016-04-13 诺瓦提斯公司 17α-羟化酶/C17,20-裂合酶抑制剂
EP2968219B1 (fr) 2013-03-14 2019-04-24 Pellficure Pharmaceuticals, Inc. Nouvelle thérapie pour le carcinome de la prostate
CA2960750A1 (fr) 2014-09-12 2016-03-17 Pellficure Pharmaceuticals, Inc. Compositions et methodes de traitement d'un carcinome de la prostate
CA3044812A1 (fr) 2016-10-24 2018-05-03 Pellficure Pharmaceuticals Inc. Compositions pharmaceutiques de 5-hydroxy-2-methylnaphtalene-1, 4-dione

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL302932A (fr) * 1962-12-31
US4891367A (en) * 1987-04-22 1990-01-02 Merrell Dow Pharmaceuticals Inc. 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors

Also Published As

Publication number Publication date
CN88102176A (zh) 1988-11-23
DK217588D0 (da) 1988-04-21
AU606677B2 (en) 1991-02-14
HU198511B (en) 1989-10-30
IL86139A (en) 1993-02-21
PH24090A (en) 1990-03-05
FI88397C (fi) 1993-05-10
NZ224288A (en) 1989-12-21
EP0288053B1 (fr) 1991-09-11
HUT47307A (en) 1989-02-28
NO881746D0 (no) 1988-04-21
NO169346B (no) 1992-03-02
FI88397B (fi) 1993-01-29
AU1471988A (en) 1988-10-27
PT87294A (pt) 1988-05-01
NO169346C (no) 1992-06-10
FI881877A0 (fi) 1988-04-21
NO881746L (no) 1988-10-24
CA1326234C (fr) 1994-01-18
ES2038712T3 (es) 1993-08-01
IL86139A0 (en) 1988-11-15
KR880012633A (ko) 1988-11-28
JPS63284195A (ja) 1988-11-21
EP0288053A1 (fr) 1988-10-26
ATE67211T1 (de) 1991-09-15
PT87294B (pt) 1992-08-31
KR960015037B1 (ko) 1996-10-24
JP2711672B2 (ja) 1998-02-10
GR3002713T3 (en) 1993-01-25
DE3864725D1 (de) 1991-10-17
FI881877A (fi) 1988-10-23
DK217588A (da) 1988-10-23

Similar Documents

Publication Publication Date Title
ZA882717B (en) 17beta-(cyclopropylamino)-androst-5-eb-3beta-ol and related compounds useful as c17-20 lyase inhibitors
EP0413270A3 (en) 4-substituted 17beta-(cyclopropylamino)androst-5-en-3beta-ol and related compounds useful as c17-20 lyase inhibitors
IL95359A0 (en) 4-substituted 17beta-(cyclopropylamino-androst-5-en-3beta-ol and related compounds useful as c17-20 lyase inhibitors
ZA882715B (en) 17beta-(cyclopropyloxy)-androst-5-en-3beta-ol and related compounds useful as c17-20 lyase inhibitors
EP0305181A3 (en) Ethyl-(+)-apovincaminate for treating demyelinization clinical patterns of autoimmune origin
HU911039D0 (en) Process for the production of hydroxymethyl-indolizidine and kynolizidine derivatives